Navigation Links
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Date:2/3/2009

igel (www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains forward-looking statements, including, but not limited to, statements related to the potential efficacy of R788, enrollment rate in clinical trials of R788, Rigel's plans to pursue clinical development of its product candidates, including R788, the market opportunity for its product candidates, expansion of and changes in its product portfolio, Rigel's plans to pursue collaboration partnerships for product candidates, the estimated charge related to the workforce reduction, the sufficiency of Rigel's cash and cash equivalents to fund current and projected development and operating plans, and Rigel's cash and cash equivalent balance at December 31, 2009. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Rigel's actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of Rigel's product candidates, including risks related to the timing and success of clinical trials, and potential problems that may arise in the clinical testing and approval process, and
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
2. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
3. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
6. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
(Date:7/3/2015)... , July 3, 2015 A ... of hypertension, diabetes and thyroid disorders in ... and a major conference dedicated to these diseases. ... Diabetes Online , Manage Hypertension Online and ... operated by EXCEMED - combine the world,s ...
(Date:7/2/2015)... 3 juillet 2015 BGI a annoncé aujourd,hui ... de l,ADN situé à Hong Kong ... College of Pathologists  (Collège des pathologistes américains, ou ... Hong Kong constituent le premier laboratoire ... la certification du CAP en Chine, car il ...
Breaking Medicine Technology:New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2
... 20, 2011 Reportlinker.com announces that a new ... Levosimendan - Comprehensive patent search ... Eliminate unnecessary risk with the industry benchmark ... is a regularly updated, professional patent search performed ...
... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... outsourcing company with operations in China and the United ... for the first quarter of 2011 after the New ... (which will be Wednesday morning, May 11, 2011 Shanghai ...
Cached Medicine Technology:Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release 2
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients ... existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, the ... , offering timely lawsuit updates and ovarian cancer warning information. The site is routinely ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
(Date:7/2/2015)... ... ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, as ... first poem, and three years later he was publishing an entire book of poetry. He ... world. "I have always believed that the best way to lift yourself up, is in ...
(Date:7/2/2015)... ... 2015 , ... Six months ahead of his 80th birthday, Don Stevenson has ... money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington ... by mid-September. He left Glasgow, Mont. yesterday morning and is making his way to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... lessons learned might one day lead to vaccine that works ... to develop an AIDS vaccine has failed, but researchers report ... next one more effective. , "It,s raised a whole new ... to answer to get us to a successful vaccine," said ...
... NEW YORK, Nov. 13 HMS Holdings Corp. (Nasdaq:,HMSY) ... Inc. Fall,Investment Conference, which will be held November 18-19, ... CFO, will present on Tuesday, November 18th at 11:00 ... is the nation,s leader in,coordination of benefits and program ...
... N.J., Nov. 13 Medco Health,Solutions, Inc. (NYSE: ... Jr., and other members of the Medco senior leadership ... financial results and,business outlook to analysts and investors during ... titled "Inventing World-Class Healthcare,Solutions," is scheduled to begin at ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
... Hospital Medical,Center (Northridge) credits TeleHealth Services, TIGR ... organization,s recent awards and top,accreditation, all of ... as its medical experts provide superior levels ... care facility located in Northridge, CA,Northridge recently ...
Cached Medicine News:Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Medco to Webcast 2008 Analyst Day Conference 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3
Architect ci8200 is a flexible solution for your evolving laboratory offering high productivity, one report and one operator interface for both chemistry and immunoassay testing....
... The Bayer Immuno 1 ... access immunoassay instrument with over ... reproductive endocrinology, tumor marker, therapeutic ... testing can be performed on ...
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay ... random access benchtop analyzer ... of assays, with panels ... reproductive, thyroid, infectious disease, ...
Medicine Products: